Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IDYA NASDAQ:IMCR NASDAQ:TARS NASDAQ:TRML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIDYAIDEAYA Biosciences$24.50-1.3%$21.48$13.45▼$44.42$2.17B0.03970,209 shs883,552 shsIMCRImmunocore$35.17-0.3%$34.06$23.15▼$40.88$1.77B0.77249,677 shs217,797 shsTARSTarsus Pharmaceuticals$41.50-2.2%$41.75$20.08▼$57.28$1.78B0.8549,077 shs442,107 shsTRMLTourmaline Bio$19.77+5.4%$17.46$11.56▼$29.79$481.60M2148,493 shs246,369 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIDYAIDEAYA Biosciences+5.08%+12.40%+14.00%+30.68%-41.18%IMCRImmunocore-2.16%-2.60%+10.18%+16.94%-10.89%TARSTarsus Pharmaceuticals+0.52%+2.51%+2.51%-15.12%+50.23%TRMLTourmaline Bio-1.00%+0.81%+10.68%+11.01%+13.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIDYAIDEAYA Biosciences4.1857 of 5 stars4.41.00.04.42.41.70.0IMCRImmunocore1.4779 of 5 stars3.30.00.00.02.42.50.0TARSTarsus Pharmaceuticals1.5231 of 5 stars3.50.00.00.01.41.70.6TRMLTourmaline Bio1.9085 of 5 stars3.51.00.00.02.22.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIDYAIDEAYA Biosciences 2.86Moderate Buy$47.5594.06% UpsideIMCRImmunocore 2.55Moderate Buy$58.8967.44% UpsideTARSTarsus Pharmaceuticals 3.00Buy$66.6760.64% UpsideTRMLTourmaline Bio 3.00Buy$49.33149.54% UpsideCurrent Analyst Ratings BreakdownLatest TRML, IDYA, IMCR, and TARS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025IDYAIDEAYA BiosciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy7/10/2025IDYAIDEAYA BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$25.007/9/2025IDYAIDEAYA BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$57.00 ➝ $30.006/26/2025IDYAIDEAYA BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$44.006/26/2025IDYAIDEAYA BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$44.006/2/2025IMCRImmunocoreHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.006/2/2025TARSTarsus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$75.005/27/2025IMCRImmunocoreDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.005/27/2025TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$72.005/22/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.005/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIDYAIDEAYA Biosciences$7M306.53N/AN/A$12.25 per share2.00IMCRImmunocore$310.20M5.70N/AN/A$7.20 per share4.88TARSTarsus Pharmaceuticals$182.95M9.53N/AN/A$5.87 per share7.07TRMLTourmaline BioN/AN/AN/AN/A$11.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIDYAIDEAYA Biosciences-$274.48M-$3.59N/AN/AN/AN/A-29.28%-27.68%8/5/2025 (Estimated)IMCRImmunocore-$51.09M-$0.43N/AN/AN/A-6.48%-5.86%-2.09%8/6/2025 (Estimated)TARSTarsus Pharmaceuticals-$115.55M-$2.73N/AN/AN/A-44.91%-39.72%-25.74%8/6/2025 (Estimated)TRMLTourmaline Bio-$73.21M-$3.21N/AN/AN/AN/A-26.75%-26.11%8/6/2025 (Estimated)Latest TRML, IDYA, IMCR, and TARS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IMCRImmunocore-$0.21N/AN/AN/AN/AN/A8/14/2025Q2 2025TARSTarsus Pharmaceuticals-$0.41N/AN/AN/A$95.81 millionN/A8/14/2025Q2 2025TRMLTourmaline Bio-$0.95N/AN/AN/AN/AN/A8/5/2025Q2 2025IDYAIDEAYA Biosciences-$0.85N/AN/AN/A$3.48 millionN/A5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A5/2/2025Q1 2025TRMLTourmaline Bio-$0.91-$0.89+$0.02-$0.89N/AN/A5/1/2025Q1 2025TARSTarsus Pharmaceuticals-$0.69-$0.64+$0.05-$0.64$72.50 million$78.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIDYAIDEAYA BiosciencesN/A13.9213.92IMCRImmunocore1.036.366.31TARSTarsus Pharmaceuticals0.215.575.54TRMLTourmaline BioN/A33.8733.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIDYAIDEAYA Biosciences98.29%IMCRImmunocore84.50%TARSTarsus Pharmaceuticals90.01%TRMLTourmaline Bio91.89%Insider OwnershipCompanyInsider OwnershipIDYAIDEAYA Biosciences2.50%IMCRImmunocore10.40%TARSTarsus Pharmaceuticals8.97%TRMLTourmaline Bio13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIDYAIDEAYA Biosciences8087.58 million85.39 millionOptionableIMCRImmunocore32050.23 million45.01 millionOptionableTARSTarsus Pharmaceuticals5042.01 million38.25 millionOptionableTRMLTourmaline Bio4425.68 million22.35 millionOptionableTRML, IDYA, IMCR, and TARS HeadlinesRecent News About These CompaniesJennison Associates LLC Cuts Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)July 22 at 6:46 AM | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives $49.33 Average Price Target from AnalystsJuly 22 at 2:11 AM | americanbankingnews.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives Consensus Rating of "Buy" from BrokeragesJuly 19, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Shares Down 2.1% - Should You Sell?July 16, 2025 | marketbeat.comTourmaline Bio Inc News (TRML) - Investing.comJuly 3, 2025 | investing.comTRML - Tourmaline Bio Inc Dividends - MorningstarJune 26, 2025 | morningstar.comMTRML - Tourmaline Bio Inc Executives - MorningstarJune 24, 2025 | morningstar.comMTourmaline Bio Elects Directors and Ratifies AuditorJune 6, 2025 | tipranks.comH.C. Wainwright maintains $50 target on Tourmaline Bio stockMay 29, 2025 | uk.investing.comH.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 ResultsMay 29, 2025 | msn.comBMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)May 23, 2025 | msn.comTourmaline shares waver as investors mull mid-stage pacibekitug dataMay 21, 2025 | thepharmaletter.comTTourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease winMay 20, 2025 | fiercebiotech.comFTourmaline Bio posts mid-stage data for anti-inflammatory agentMay 20, 2025 | msn.comTourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 InhibitionMay 20, 2025 | seekingalpha.comTourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025May 19, 2025 | globenewswire.comTourmaline Bio Reports Q1 2025 Financial ResultsMay 7, 2025 | tipranks.comWhy Tourmaline Bio, Inc.’s (TRML) Stock Is Down 7.00%May 3, 2025 | aaii.comATourmaline Bio, Inc.: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 3, 2025 | finanznachrichten.deTourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 2, 2025 | globenewswire.comTourmaline Bio initiated with a Buy at ChardanApril 23, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRML, IDYA, IMCR, and TARS Company DescriptionsIDEAYA Biosciences NASDAQ:IDYA$24.50 -0.33 (-1.33%) Closing price 04:00 PM EasternExtended Trading$24.50 +0.00 (+0.02%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Immunocore NASDAQ:IMCR$35.17 -0.10 (-0.28%) Closing price 04:00 PM EasternExtended Trading$35.22 +0.05 (+0.16%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Tarsus Pharmaceuticals NASDAQ:TARS$41.50 -0.94 (-2.21%) Closing price 04:00 PM EasternExtended Trading$41.52 +0.02 (+0.06%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.Tourmaline Bio NASDAQ:TRML$19.77 +1.02 (+5.44%) Closing price 04:00 PM EasternExtended Trading$19.88 +0.11 (+0.53%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
